In the News
PPD prices IPO, seeking $1.5bn at a $9bn valuation
PPD sets terms of planned initial public offering.
PPD begins trading on Nasdaq
PPD announces the pricing of its initial public offering of 60 million shares of its common stock at $27.00 per share.
Wilmington pharmaceutical company PPD goes public
Shares of PPD’s common stock begin trading on The Nasdaq Global Select Market under the symbol “PPD.”
China’s evolving regulatory environment: Special report
Alistair Davidson, Guoliang Liu and Bill Wang assess how the clinical trial market has responded over the past few years and analyze the future of the China market.
PPD files for IPO
PPD announces the launch of its initial public offering of 60 million shares of its common stock.
PPD eyes China expansion as opportunity grows
PPD is expanding its operations and leadership team in China to provide enhanced clinical development, laboratory, regulatory, site conduct, patient access and post-approval services for international and China-based biopharmaceutical companies.
PPD sets out $1B IPO plans as it launches new China labs
The initial public offering price is expected to be between $24.00 and $27.00 per share.
PPD going public – again – with stock offering targeting at least $1.44B
PPD has applied to have its common stock approved for listing on The Nasdaq Global Select Market under the symbol “PPD.”
Why site collaboration is key to abating the ‘one and done’ syndrome
There is no question that clinical trial management is becoming more complex. Instead of engaging with patients, an inordinate amount of time is spent learning new systems, completing redundant required training and reentering the same data multiple times.
